Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients

Bow, Eric J.; Louie, Thomas; Riben, Peter D.; McNaughton, R. D.; Harding, G. K. M.; Ronald, Allan

doi:10.1016/0002-9343(84)90777-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Prevention Of Infections In Neutropenic Patients1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1988

2012

Publication Types

Select...

Book3

Article2

Other1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 28 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with profound granulocytopenia and particularly those receiving chemotherapy, which disrupts the integrity of the gastrointestinal mucosa, are at risk for gram-negative bacteremia from a bowel source. TMP-SMX has been previously used as prophylaxis for such infections, but with variable success (72,150,591,840). Fluoroquinolones have a broad spectrum of activity against potential gram-negative pathogens, including P. aeruginosa, and therefore might be predicted to be useful prophylactic agents in neutropenic patients.…”

Section: Prevention Of Infections In Neutropenic Patientsmentioning

confidence: 99%

Fluoroquinolone antimicrobial agents.

Wolfson¹,

Hooper²

1989

Clinical Microbiology Reviews

View full text Add to dashboard Cite

show abstract

Section: Prevention Of Infections In Neutropenic Patientsmentioning

confidence: 99%

Fluoroquinolone antimicrobial agents.

Wolfson¹,

Hooper²

1989

Clinical Microbiology Reviews

View full text Add to dashboard Cite

show abstract

Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy

Gafter‐Gvili¹,

Fraser²,

Wetering³

et al. 2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Our review demonstrated that prophylaxis significantly reduced all-cause mortality. The most significant reduction in mortality was observed in trials assessing prophylaxis with quinolones. The benefit demonstrated in our review outweighs harm, such as adverse effects, and development of resistance, since all-cause mortality is reduced. Since most trials in our review were of patients with haematologic cancer, prophylaxis, preferably with a quinolone, should be considered for these patients.

show abstract